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ABSTRACT
The lower morbidity and mortality of reduced-intensity conditioning (RIC) regimens have allowed allogeneic
hematopoietic cell transplantation (HCT) in older patients. Unrelated umbilical cord blood (UCB) has been
investigated as an alternative stem cell source to suitably HLA matched related (MRD) and adult volunteer
unrelated donors. We hypothesized that RIC HCT using UCB would be safe and efficacious in older patients,
and compared the treatment-related mortality (TRM) and overall survival (OS) of RIC HCT in patients older
than 55 years using either MRD (n5 47) or, in patients with no 5 of 6 or 6 of 6 HLA compatible related donors,
UCB (n5 43). RIC regimen consisted of total-body irradiation (TBI; 200 cGy) and either cyclophosphamide and
fludarabine (n5 69), or busulfan and fludarabine (n5 16) or busulfan and cladribine (n5 5). The median age of
MRD and UCB cohorts was 58 (range, 55-70) and 59 (range, 55-69) years, respectively. acute myelogenous leu-
kemia/myelodysplastic syndrome (AML/MDS) (50%)was themost common diagnosis. AllMRDgrafts were 6 of
6HLAmatched to the recipient. Among patients undergoing UCBHCT, 88% received 2UCB units to optimize
cell dose and 93% received 1-2 HLA mismatched grafts. The median follow-up for survivors was 27 (range: 12-
61) months. The 3-year probabilities of progression-free survival (PFS; 30% versus 34%, P5 .98) and OS (43%
versus 34%, P 5 .57) were similar for recipients of MRD and UCB. The cumulative incidence of grade II-IV
acute graft-versus-host (aGVHD) disease (42% versus 49%, P 5 .20) and TRM at 180-days (23% versus 28%,
P5 .36) were comparable. However, UCB recipients had a lower incidence of chronic graft-versus-host disease
(cGVHD) at 1 year (40% versus 17%, P 5 .02). On multivariate analysis, graft type had no impact on TRM or
survival, and theHCT comorbidity index score was the only factor independently predictive for these endpoints.
Our study supports the use of HLA mismatched UCB as an alternative graft source for older patients who need
a transplant but do not have an MRD. The use of RIC and UCB extends the availability of transplant therapy to
older patients previously excluded on the basis of age and lack of a suitable MRD. A careful review of existing
comorbidities is necessary when considering older patients for HCT.
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Allogeneic hematopoietic cell transplantation
(HCT) is an effective therapy for a variety of malignant282and nonmalignant hematologic disorders. The high
rates of treatment-related morbidity and mortality
(TRM) observed with traditional myeloablative
RIC HCT in older patients 283conditioning regimens have typically restricted the use
of allogeneic HCT to young and relatively healthy
patients. Many adult hematologic malignancies mani-
fest clinically in the sixth or seventh decade of life, and
because of advanced age and high-risk for TRM, these
patients are usually excluded from most conventional
myeloablative allogeneic HCT protocols. The advent
of reduced-intensity conditioning (RIC) regimens that
primarily rely on the graft-versus-tumor effect has
allowed allogeneic HCT as a treatment option for
these older patients. This approach has been shown
to be feasible, lead to long-term engraftment, exhibit
a graft-versus-malignancy effect, and result in
acceptable TRM [1-3].
Although a human leukocyte antigen (HLA)
matched related donor (MRD) is the preferred donor
source, it is available for less than 30% of patients
requiring allogeneic HCT [4,5]. Transplantation
from adult volunteer unrelated donors also remains
limited by the availability of fully HLAmatched grafts,
and increased HLA disparity in this setting adversely
affects overall survival (OS) and increases the risk of
graft-versus-host disease (GVHD) [5,6]. Unrelated
umbilical cord blood (UCB) has been investigated as
an alternative source for hematopoietic stem cells.
We have previously reported that UCB HCT using
an RIC regimen produces high rates of engraftment
with tolerable toxicity [7-9].
We hypothesized that for older patients without
a MRD, UCB could lead to comparable survival and
TRM, thus extending the availability ofHCT as a ther-
apeutic option for patients who would otherwise be in-
eligible for transplantation because of lack of a suitable
donor. We therefore conducted a study comparing the
safety and efficacy of allogeneic HCT after RIC regi-
men in patients older than 55 years using either
MRD or UCB in patients with no MRD.
METHODS
Patient Characteristics
Eligibility criteria for HCT using RIC at our insti-
tution include older age ($55 years for MRD and$45
years for UCB), presence of significant comorbidity,
and history of previous autologous transplant or exten-
sive therapy. Data were collected prospectively on 90
consecutive patients between 55-70 years of age who
received RIC HCT between January 2000 and De-
cember 2005 using eitherMRD (n5 47) or, in patients
with no 5 of 6 or 6 of 6 HLA compatible related do-
nors, UCB (n5 43). The primary indication for using
RIC instead of a conventional myeloablative prepara-
tive regimen for all patients was age $55 years. Pa-
tients were considered for UCB HCT if they had no
HLA-compatible related donors (5 of 6 or 6 of 6
HLA-A, B, or DRB1 matches).Pretransplantation comorbidities were scored ret-
rospectively for all patients using the HCT-specific
comorbidity index (HCT CI) described by Sorror
et al [10]. The comorbidities captured by this tool
include cardiac disorders, cerebrovascular disease,
diabetes, altered hepatic function, infection, inflam-
matory bowel disease, obesity, peptic ulcer disease,
psychiatric disturbance, pulmonary abnormalities, re-
nal insufficiency, and rheumatologic disorders. Scores
are assigned to various comorbidities based on their
severity and a final composite score is then calculated
and patients can be assigned to 1 of 3 risk groups:
low risk (score 0), intermediate risk (score 1-2), and
high risk (score $3).
Patients were classified as having standard- or
high-risk disease. Standard-risk disease included acute
leukemia in first complete remission (CR), chronic
myelogenous leukemia (CML) in the first chronic
phase, myelodysplastic syndrome (MDS)—refractory
anemia, and nonmalignant hematologic disorders; all
other diagnoses were categorized as high-risk disease.
Treatment Plan
The majority of patients (n 5 69) underwent
conditioning with a regimen that included cyclophos-
phamide (50 mg/kg intravenously on day –6), fludara-
bine (40 mg/m2 intravenously daily from days –6
through –2), and 200 cGy total-body irradiation
(TBI; on day –1). Prior to September 2001, patients
received a regimen (n 5 16) using busulfan (2 mg/kg
orally every 12 hours for 4 doses on days –8 and –7)
with the same doses of fludarabine and TBI, or a regi-
men (n 5 5) using the same dose of busulfan and TBI
with cladribine (10 mg/m2 intravenously daily from
days –6 through –2). Equine antithymocyte globulin
(ATG) 15 mg/kg intravenously every 12 hours for 6
doses from days –3 to –1 was added to a subgroup of
patients who had not received chemotherapy within
3 months of HCT or a previous autologous transplant
(n 5 23). All patients received GVHD prophylaxis
with cyclosporine (days –3 to at least1100) and myco-
phenolate mofetil (MMF; days –3 to at least 130).
Granulocyte colony-stimulating factor (G-CSF) 5
mg/kg/day intravenously was administered to all pa-
tients until the absolute neutrophil count (ANC) was
more than 2.5  109/L for 2 days. The treatment pro-
tocols were approved by the University of Minnesota
institutional review board, and all patients gave in-
formed consent prior to transplantation.
MRD and UCB Grafts
All related donor grafts were 6 of 6 HLA matched
to the recipient and the target cell dose was at least 3
108 NC/kg. Forty-four patients undergoing MRD
HCT received G-CSF mobilized peripheral blood
stem cell (PBSC) grafts, and 1 patient received
a bone marrow graft. In addition, because of
284 N. S. Majhail et al.inadequate donor mobilization, 2 patients received
grafts derived from both PBSC and bone marrow.
Our UCB selection criteria for adults have been
previously published [7,8,11]. UCB grafts were
matched at least 4 of 6 HLA-A, -B (antigen level),
and -DRB1 (allele level) to the recipient, and in
patients receiving 2 UCB units, to each other.
Thirty-eight (88%) patients undergoing UCB HCT
received grafts consisting of 2 UCB units to optimize
cell dose and 40 (93%) received at least 1-2 HLA
mismatched units. The median total cryopreserved
nucleated cell dose was 3.7  107 NC/kg (range:
1.6-7.8  107 NC/kg) and CD341 dose was 4.2 
105 cells/kg (range: 1.3-16.6  105 cells/kg). UCB
units were thawed using the method described by
Rubinstein et al [12].
Donor Chimerism Analysis
Donor chimerism was determined serially on
marrow and/or blood samples on days 121-28, 160,
1100, 6 months, and annually after HCT. Chimerism
analysis was performed using quantitative PCR of
informative polymorphic variable-number tandem
repeat (VNTR) or short tandem repeat (STR) regions
in recipient and donor [13,14], and has been described
previously [7].
Study Definitions and Statistical Analysis
The primary endpoint was probability of progres-
sion-free survival (PFS). Other study endpoints in-
cluded probability of overall survival (OS) and
cumulative incidences of sustained donor engraftment,
acute and chronic GVHD (aGVHD, cGVHD), and
TRM. PFS was defined as survival in CR or stable par-
tial remission (PR); recurrence after achieving a CR or
an increase in existing or new disease sites following
a stable PR was considered disease progression. CR
was defined as complete absence of disease on clinical,
radiologic, and if indicated, pathologic evaluation. PR
was defined as $50% reduction in sites of known dis-
ease. Failure to achieve a PR was defined as persistent
disease. Sustained donor engraftment was defined as
neutrophil recovery with donor hematopoiesis by day
42 after transplant. Time of neutrophil engraftment
was defined as first of 3 consecutive days with an
ANC .0.5  109/L. Complete donor chimerism was
defined as marrow reconstitution of donor origin of
at least 90%. Ten patients (UCB 5 5, MRD 5 5)
were censored from engraftment analysis because of
death prior to day 21 and before the status of donor
chimerism could be ascertained. Standard clinical cri-
teria were used to diagnose and grade GVHD [15,16].
TRM was defined as death within 180 days following
HCT without disease progression or relapse.
Comparison of patient and transplant characteris-
tics was performed using chi-square, Fisher’s exact, orWilcoxon’s rank sum test as appropriate. Cumulative
incidence of engraftment, TRM, and GVHD was
calculated by treating deaths from other causes as com-
peting risks [17]. The Kaplan-Meier method was used
to plot survival curves for PFS and OS [18]. Both uni-
variate and multivariate Cox regressions were per-
formed with TRM, PFS, and OS as the outcomes
[19]. Variables were included in themultivariate model
if they were conceptually important, or if they ap-
proached or obtained statistical significance in the uni-
variate regression. All multivariate models included
donor type (UCB versus MRD) and were adjusted
for age at transplant, sex, time from diagnosis to trans-
plant, history of previous transplant, disease risk,
recipient-donor HLA disparity, recipient-donor cyto-
megalovirus (CMV) serologic status, conditioning reg-
imen, use of ATG, aGVHD, cGVHD, and HCT CI
score. Acute GVHD (aGVHD) was treated as a time-
dependent variable. Event times were measured from
date of transplantation to date of death or last contact.
All P-values were 2 sided. Analyses were performed in
SAS 8.2 and SAS 9.1 (Cary, North Carolina). The
analysis was based on follow-up through June 2007.
RESULTS
Patient Characteristics
Patient, disease, and transplant characteristics are
summarized in Table 1. The median age at transplant
for the entire cohort was 59 years (range: 55-70 years).
A significantly higher proportion of patients undergo-
ing UCBHCT received ATGwith their conditioning.
All UCB grafts were CMV seronegative. UCB units
also had a significantly lower cryopreserved cell dose
and CD341 cell dose.
Sixty-eight (76%) patients had at least 1 comorbid
condition; however, the distribution ofHCTCI scores
among the 2 groups was comparable. The common
pretransplant comorbidities observed in our cohort
were pulmonary disorders (DLCO and/or FEV1
#80%, dyspnea, or requiring oxygen; n5 47), hepatic
abnormalities (chronic hepatitis, liver cirrhosis or bil-
irubin, serum transaminase levels more than the upper
limit of normal; n 5 17), cardiac abnormalities (coro-
nary artery disease, congestive heart failure, myocar-
dial infarction, or LVEF #50%; n 5 16), history of
prior malignancy (n 5 11), psychiatric disturbances
(depression or anxiety needing treatment; n 5 10),
diabetes needing treatment (n 5 6), obesity (body
mass index .35 kg/m2; n 5 6), and infections (n 5 5).
Survival
The median follow-up of survivors was 27 months
(range: 12-61 months). The probabilities of 3-year
PFS and OS were comparable between the 2 groups
(Table 2). The probability of PFS at 3 years was
30% (95% confidence intervals [CI], 16%-44%) for
RIC HCT in older patients 285Table 1. Patient, Disease, and Transplant Characteristics
Characteristics MRD (n 5 47) UCB (n 5 43) P-value
Median age, years (range) 58 (55-70) 59 (55-69) .22
Gender, male 33 (70%) 32 (74%) .66
Median weight, kilograms (range) 78 (55-120) 79 (50-130) .96
Race .88
White 43 (91%) 38 (88%)
Other 4 (9%) 5 (12%)
Diagnosis .07
Acute myelogenous leukemia 10 (21%) 19 (44%)
Acute lymphoblastic leukemia 2 (4%) 2 (5%)
Chronic myelogenous leukemia 2 (4%) 1 (2%)
Chronic lymphocytic leukemia 3 (7%) 2 (5%)
Myelodysplastic syndrome 6 (13%) 10 (23%)
Non-Hodgkin lymphoma 14 (30%) 7 (16%)
Hodgkin lymphoma 2 (4%) 0
Multiple myeloma 6 (13%) 0
Other* 2 (4%) 2 (5%)
Disease risk† .33
Standard 9 (19%) 12 (28%)
High 38 (81%) 31 (72%)
Prior HCT‡ 9 (19%) 3 (7%) .09
Median time from diagnosis to HCT,
months (range)
25 (3-154) 13 (3-250) .24
HCT-specific comorbidity index score§ .10
0 7 (16%) 15 (36%)
1-2 19 (43%) 13 (31%)
$3 18 (41%) 14 (33%)
Conditioning regimen .13
Cy/Flu/TBI 33 (70%) 36 (84%)
Other¶ 14 (30%) 7 (16%)
ATG used in conditioning 6 (13%) 17 (40%) \.01
HLA compatibilityt \.01
6 of 6 antigen match 47 (100%) 3 (7%)
5 of 6 antigen match 0 13 (30%)
4 of 6 antigen match 0 27 (63%)
Recipient-donor CMV serologic status .02
Recipient negative-donor negative 16 (34%) 18 (42%)
Recipient negative-donor positive 8 (17%) 0
Recipient positive 23 (49%) 25 (58%)
Median cell dose, 108 NC/kg (range) 9.2 (3.0-21.2) 0.4 (0.2-0.8) \.01
Median CD341 cell dose, 106 cells/kg
(range)
5.3 (1.2-15.5) 0.4 (0.1-1.7) \.01
Median follow up, months (range) 37 (18-61) 24 (12-44) .33
MRD indicatesmatched related donor; UCB, unrelated umbilical cord blood donor;MDS,myelodysplastic syndrome;HCT, hematopoietic cell
transplantation; ATG, antithymocyte globulin; Cy/Flu/TBI, cyclophosphamide/fludarabine/total-body irradiation; HLA, human leukocyte
antigen; CMV, cytomegalovirus; NC, nucleated cells.
*Includes 1 patient each with renal cell carcinoma and myelofibrosis in MRD group and renal cell carcinoma and aplastic anemia in UCB group.
†Standard-risk disease—acute leukemia in first complete remission, chronic myelogenous leukemia in first chronic phase, myelodysplastic syn-
drome refractory anemia, nonmalignant hematologic disorder; high-risk disease—all other disease categories.
‡All had prior autologous HCT except for 1 patient in MRD group who had received an MRDmyeloablative allogeneic HCT for MDS 8 years
prior.
§Excludes 4 patients (MRD 5 3, UCB 5 1) for whom sufficient data was not available to calculate the HCT-specific comorbidity score.
¶Includes busulfan/fludarabine/TBI (n 5 16) and busulfan/cladribine/TBI (n 5 5).
tWorst HLA match for patients undergoing UCB transplantation using 2 UCB units.recipients ofMRD and 34% (95% [CI], 19%-48%) for
UCB recipients (P 5 .98). The probability of OS at 3
years was 43% (95% CI, 29%-58%) for MRD and
34% (95% CI, 17%-50%) for UCB recipients (P 5
.57) (Figure 1).
On univariate analysis, PFS was significantly worse
in patients who had received a previous transplant (haz-
ard ratio [HR] 2.1, 95% CI 1.0-4.1, P 5 .04), and wassignificantly better in recipients of Cy/Flu/TBI condi-
tioning regimen (HR0.5, 95%CI, 0.3-0.9,P5 .03) and
in patients with a pretransplant HCT CI score of\3
(HR 0.5, 95% CI, 0.3-0.8, P 5 .009). The same vari-
ables also affected OS; OS was significantly worse in
patients who had received a previous transplant (HR
2.6, 95% CI, 1.3-5.2, P 5 .007) and was significantly
better in patients transplanted using the Cy/Flu/TBI
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Endpoint All patients (n 5 90) MRD (n 5 47) UCB (n 5 43) P-value*
3-Year PFS (95% CI) 32% (22-43) 30% (16-44) 34% (19-48) .98
3-year OS (95% CI) 39% (28-50) 43% (29-58) 34% (17-50) .57
Sustained donor engraftment at 42 days
(95% CI)†‡
95% (93-97) 100% 89% (80-99) .05
Grade 2-4 acute GVHD (95% CI)† 45% (34-47) 42% (27-57) 49% (32-65) .20
Chronic GVHD at 1 year (95% CI)† 29% (18-40) 40% (23-56) 17% (5-29) .02
180-Day TRM (95% CI)† 26% (16-35) 23% (11-36) 28% (14-41) .36
MRD indicates matched related donor; UCB, unrelated umbilical cord blood donor; TRM, transplant-related mortality; GVHD, graft-versus-
host disease; PFS, progression free survival; OS, overall survival; CI, confidence intervals.
*P-value for comparison between MRD and UCB.
†Cumulative incidence.
‡Ten patients (MRD 5 5, UCB 5 5) were censored for engraftment analysis because of death prior to analysis for donor chimerism.regimen (HR 0.4, 95% CI, 0.2-0.8, P 5 .006) or with
pretransplant HCT CI score of\3 (HR 0.4, 95% CI,
0.2-0.7, P 5 .001). Pretransplant HCT CI score was
the only independent predictor for both PFS and for
OS onCox regression analysis (Table 3). PFS at 3 years
was 50% (95% CI, 29%-71%), 34% (95% CI, 17%-
50%), and 16% (95%CI, 0%-33%) forHCTCI scores
of 0, 1-2, and$3, respectively (P5 .03). OS at 3-years
Figure 1. Probability of (A) PFS and (B) OS. The probability of PFS
and OS at 3 years between the 2 graft sources was comparable.for the 3 risk groups was 56% (95% CI, 33%-78%),
46% (95% CI, 29%-64%) and 23% (95% CI, 5%-
40%), respectively (P5 .01).
Engraftment, GVHD, and TRM
The cumulative incidence of TRMand grade II-IV
aGVHD was also similar, whereas the incidence of
sustained donor engraftment and cGVHD was lower
in the UCB group (Table 2 and Figure 2).
TRM was higher among patients with HCT CI
score of $3. The cumulative incidence of TRM at
180 days was 14% (95% CI, 0%-28%), 19% (95%
CI, 5%-32%) and 44% (95% CI, 26%-62%) for pa-
tients with HCT CI scores of 0, 1-2, and $3, respec-
tively (P \ .01). On Cox regression analysis, the
HCT CI score was the only independent predictor
of TRM; compared to patients with a higher score,
those with a score of\3 had an HR for TRM of 0.3
(95% CI, 0.1-0.7, P 5 .006).
Twenty-six MRD and 27 UCB HCT recipients
have died. The primary causes of death were disease
progression (MRD 5 14, UCB 5 12), infections
(MRD5 6,UCB5 8), aGVHD(MRD5 5,UCB5 1),
and multiorgan failure (MRD 5 1, UCB 5 3). Two
patients from the UCB cohort died of primary graft
failure; the cause of death could not be determined
Table 3. Adjusted Cox-Regression Analysis for Factors Predicting
Progression-Free and Overall Survival
Progression-Free Survival Overall Survival
Variable HR (95% CI) P-value HR (95% CI) P-value
Donor type
MRD 1.0 1.0
UCB 1.31 (0.73-2.32) .36 1.78 (0.93-3.42) .08
HCT CI score
$3 1.0 1.0
\3 0.54 (0.30-0.96) .04 0.45 (0.24-0.85) .01
MRD indicates matched related donor; UCB, unrelated umbilical
cord blood donor; HCT CI, hematopoietic cell transplanta-
tion-specific comorbidity index; HR, hazard ratio; CI,
confidence intervals.
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UCB 5 3) have developed second malignancies fol-
lowing transplantation with a resultant 2-year
cumulative incidence of 13% (95% CI, 0%-26%).
These include 2 patients with nonmelanoma skin can-
cer, 1 patient with malignant melanoma in situ, and 1
patient who developed Epstein-Barr virus related
posttransplantation lymphoproliferative disorder 5
months after UCB transplant.
DISCUSSION
We report comparable TRM and survival follow-
ing allogeneic HCT after RIC using either MRD or
Figure 2.Cumulative incidence of (A) sustained donor engraftment,
(B) acute grade II-IV GVHD, and (C) cGVHD. The cumulative in-
cidence of aGVHD was comparable between the 2 graft sources,
whereas that for donor engraftment and cGVHD was lower in
UCB recipients.mismatched UCB in patients between 55 and 70 years
of age. Our results are also comparable to other reports
of RIC HCT using either a MRD or matched volun-
teer adult unrelated donor in older patients [2,3,20-
22]. The limitation of advanced age for patients who
could potentially benefit by allogeneic HCT has
been significantly overcome by the introduction of
RIC regimens [2,20-23]. However, the lack of suitable
donors remains a major deterrent to transplantation in
older patients. Compared to their younger counter-
parts, the already limited probability of finding an
MRD is even more restricted as their siblings may
not be healthy enough to undergo graft collections
or may poorly mobilize hematopoietic cells. The use
of UCB, however, expands the donor pool and offers
the possibility of allogeneic HCT in older patients
who otherwise lack a suitable related or unrelated
donor.
Cell dose is among the most critical determinants
of engraftment and transplant outcome following
UCB transplantation and the limited availability of he-
matopoietic stem cells from a single UCB unit has
been the main barrier to widespread use of UCB as
a donor source, especially in adults [24,25]. We have
been investigating the utilization of 2 UCB units as
a strategy to increase the total cell dose and have pre-
viously reported on the safety and efficacy of double
unit UCB transplantation in both myeloablative and
RIC settings [7,8,26]. In this study, the majority
(88%) of UCB recipients received 2 UCB units with
acceptable rates of engraftment and transplant related
deaths, supporting the use of this approach in older
patients.
Despite the use of grafts with greater HLA dispar-
ity, UCB recipients in our study had a similar inci-
dence of aGVHD and a significantly lower incidence
of cGVHD. Other studies have suggested that UCB
might be associated with a lower risk of cGVHD
[8,27-32]. However, a significantly larger proportion
of patients undergoing UCB HCT in our study also
received ATG as a part of their conditioning regimen
and ATG has been reported to decrease the risk of
cGVHD after allogeneic HCT with both myeloabla-
tive and RIC regimens [33-35].
We found the HCT CI to be a useful tool for pre-
transplant risk assessment in this cohort of older pa-
tients. In comparison to the original cohort (median
age 45 years) used by Sorror et al [10] to describe
this index, our relatively older cohort (median age 58
years) had a higher proportion of patients with 3 or
more comorbidites (37% versus 28%). Although
HCT CI score of $3 (high-risk group) was indepen-
dently predictive of PFS, TRM, and OS, no significant
difference was observed between the outcomes of
low-risk (score 0) and intermediate-risk (score 1 and
2) groups. Although age remains an important factor
determining eligibility for transplantation, the
288 N. S. Majhail et al.incorporation of risk assessment models such as the
HCT CI into decision algorithms will further assist
in selecting suitable older candidates for RIC HCT.
In conclusion, our study supports the use of HLA
mismatched UCB as an alternative graft source for
older patients who need a transplant but do not have
an MRD. Together, use of RIC and UCB markedly
extends the availability of transplant therapy to older
patients previously excluded on the basis of age and
lack of a suitableMRD.Healthy older HCT recipients
have a low and acceptable risk of TRM, and a careful
review of existing comorbidities is necessary when
considering older patients for HCT.
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